ArticleMicrobiome2026
The interplay between Peptostreptococcus and Fusobacterium as novel signatures in colorectal cancer recurrence.
Article in Microbiome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Spatial Heterogeneity of Intratumoral Microbiota and Its Roles in Tumor-Microbiota Interactions and Therapeutic Implications.Pathogens (Basel, Switzerland) · 2026Review
- Berberine prevents postoperative recurrence of colorectal cancer: a protocol for a multicenter, double-blind, randomized controlled trial.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundAfter resection surgery, recurrence occurs in more than 30% of colorectal cancer (CRC) patients. Previous studies have highlighted the role of the gut microbiota in CRC initiation and progression; however, the microbial features associated with recurrence remain not completely understood. In particular, integrated multi-omics biomarkers, the interactions between microorganisms, as well as those between microbes and the host, and their relevance to recurrence risk require further investigation.
resultsIn this study, 120 tumor mucosal samples collected during surgery from CRC patients underwent 16S rRNA gene sequencing and LC-MS metabolomic profiling. Recurrence status was determined through postoperative follow-up. Compared to the relatively minor variations in mucosal microbial and metabolomic signatures across different tumor node metastasis (TNM) stages, recurrent patients exhibited a distinct landscape. Machine learning analysis identified an integrated signature comprising five bacterial genera (Peptostreptococcus, Fusobacterium, Bacteroides, Porphyromonas, and Prevotella) and five metabolites (alanylglutamic acid, putrescine, arginine, histidine, and sebacic acid), which demonstrated strong discriminatory performance between recurrent and non-recurrent patients (AUC = 0.89). By integrating 10 biomarkers, a comprehensive risk score for patient stratification was derived. After adjusting for TNM stage, patients classified as high-risk had a significantly shorter recurrence-free survival (adjusted HR = 1.59, 95% CI 1.35-1.88, P < 0.0001). The microbial biomarkers Fusobacterium and Peptostreptococcus displayed positive correlation and were observed to co-aggregate and form dense dual-species biofilms. Further cellular and murine experiments revealed that P. anaerobius significantly enhanced the adhesion of F. nucleatum to tumor cells and its colonization of colonic mucosa. KEGG pathway analysis of differential metabolites identified enrichment of arginine and proline metabolism pathways in the recurrence group. Concurrently, arginine was found to disrupt F. nucleatum-P. anaerobius co-aggregation, while its metabolite putrescine significantly promoted dual-species biofilm formation.
conclusionOur study identified integrated microbial and metabolic features associated with CRC recurrence and proposes an exploratory risk stratification framework. Furthermore, a previously unrecognized link between pathobionts and metabolites relevant to recurrence was reported, which requires further validation in a larger independent cohort. Video Abstract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.